This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Health professional risk communication

Multaq (dronedarone) – Updated Safety Information in Regards to Hepatocellular Liver Injury – For the Public

Starting date:
March 15, 2011
Posting date:
March 15, 2011
Type of communication:
Public Communication
Source of recall:
Health Canada
General Public
Identification number:

This is duplicated text of a letter from Sanofi-aventis Canada Inc.

Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Public Communication

Health Canada Endorsed Important Safety Information on Multaq

March 15, 2011

Subject: Updated Safety Information for Multaq® (dronedarone) related to liver injury

Sanofi-aventis Canada Inc., in collaboration with Health Canada would like to inform patients of new important safety information related to liver injury, reported in patients treated with Multaq. Multaq helps control abnormal heart rate and rhythm called atrial fibrillation and can lower the risk of having to go into the hospital for heart problems.

  • Patients should discuss with their healthcare professionals this new safety information regarding Multaq treatment.
  • Patients treated with Multaq should immediately report to their doctors symptoms possibly suggesting liver injury (such as: Loss of appetite, nausea, vomiting, unusual tiredness, right upper stomach area pain or discomfort, yellowing of the skin or the whites of the eyes (jaundice), unusual darkening of the urine, or itching) and patients should consider obtaining periodic liver function tests.

Sanofi-aventis has been working with Health Canada, and the Multaq Product Monograph was revised to include this new safety information.

Please speak with your doctor or pharmacist if you have any related concerns or if you experience any other unexpected effects while taking Multaq.

Managing marketed health product-related side effects depends on health professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported side effects of marketed products are generally presumed to underestimate the risks associated with health product treatments. Any case of serious liver injury or other serious or unexpected side effects in patients receiving Multaq (dronedarone hydrochloride) should be reported to sanofi-aventis Canada Inc. or Health Canada at the following addresses:

Sanofi-aventis Canada Inc.

2150 St-Elzear Blvd. West

LAVAL, Quebec

H7L 4A8

Telephone: 1-800-267-7927

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

  • Report online at MedEffectTM Caanda
  • Call toll-free at 1-866-234-2345
  • Complete a Reporting Form and:
    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program

      Health Canada

      Postal Locator 0701E

      Ottawa, Ontario   K1A 0K9

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section.

For other health product inquiries related to this communication, please contact Health Canada at:

Marketed Health Products Directorate


Telephone: 613-954-6522


Should you have any questions regarding the new important safety update, please contact sanofi-aventis Canada Inc. toll free at 1-800-265-7927.


original signed by

Monique Furlan, B. Pharm., M. Sc.

Director, Medical Strategy and Regional Operations

sanofi-aventis Canada Inc.

Multaq: Health Canada reviewing heart-related risk

2011-07-21 | Health products


Multaq (dronedarone) – Information on Important Revisions to Product Monograph – For the Public

2011-12-08 | Health products